Because it's not derived from blood, Definity eliminates the risks associated with the use of blood-based products, according to DuPont. Definity is available through flexible dosing and administration through bolus injection or continuous intravenous infusion. DuPont believes that Definity provides a relatively long window of time for image acquisition. The vendor plans to commercially introduce Definity beginning early this fall.
By AuntMinnie.com staff writersAugust 1, 2001
Related Reading
DuPont expands radiopharmaceutical efforts in Puerto Rico, July 31, 2001
DuPont pharma divestiture could cast ripples in imaging, June 22, 2001
Bristol-Myers Squibb to buy DuPont Pharmaceuticals, June 12, 2001
DuPont closes in on fate of medical imaging business, April 9, 2001
Copyright © 2001 AuntMinnie.com